{"nctId":"NCT03602053","briefTitle":"Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia","startDateStruct":{"date":"2019-01-22","type":"ACTUAL"},"conditions":["Diarrhea","Diarrhea Rotavirus"],"count":450,"armGroups":[{"label":"ROTAVAC 5D","type":"EXPERIMENTAL","interventionNames":["Biological: ROTAVAC 5D"]},{"label":"ROTAVAC®","type":"EXPERIMENTAL","interventionNames":["Biological: ROTAVAC®"]},{"label":"Rotarix®","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Rotarix®"]}],"interventions":[{"name":"ROTAVAC®","otherNames":[]},{"name":"ROTAVAC 5D","otherNames":[]},{"name":"Rotarix®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy infant as established by medical history and clinical examination before entering the study.\n2. Age: 6-8 weeks (42-56 days, both days inclusive) confirmed by Immunization Record.\n3. Infants received age-appropriate EPI vaccines till enrolment.\n4. Ability and willingness to provide informed consent as per local consenting procedures.\n5. Parent can be contacted on phone and confirms intention to remain in the study area with the participant during the study period.\n\nExclusion Criteria:\n\n1. Presence of diarrhea or vomiting in the previous 72 hours or on the day of enrolment (temporary exclusion).\n2. Presence of fever on the day of enrolment (temporary exclusion).\n3. Acute disease at the time of enrolment (temporary exclusion).\n4. Concurrent participation in another clinical trial throughout the entire timeframe of this study.\n5. Presence of severe malnutrition (weight-for-height z-score \\< -3SD median).\n6. Any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, immunological, dermatological, neurological, cancer or autoimmune disease) as determined by medical history and/or physical examination which would compromise the child's health or is likely to result in non-conformance to the protocol.\n7. History of congenital abdominal disorders, intussusception, abdominal surgery\n8. Known or suspected impairment of immunological function based on medical history and physical examination.\n9. Prior receipt or intent to receive rotavirus and other age specified EPI vaccines outside of the study center and during study participation.\n10. A known sensitivity or allergy to any component of the study vaccine.\n11. Clinically detectable significant congenital or genetic defect.\n12. History of persistent diarrhea (defined as diarrhea more than 14 days).\n13. Participant's parents not able, available or willing to accept active follow-up by the study staff.\n14. Has received any immunoglobulin therapy and/or blood products since birth or planned administration during the study period.\n15. History of chronic administration (defined as more than 14 days) of immunosuppressants including corticosteroids. Infants on inhaled or topical steroids may be permitted to participate in the study.\n16. History of any neurologic disorders or seizures.\n17. Any medical condition in the parents/infants that, in the judgment of the investigator, would interfere with or serves as a contraindication to protocol adherence or a participant's parent's/legally acceptable representative's ability to give informed consent.\n18. Participant is a direct descendant (child or grandchild) of any person employed by the Sponsor, the CRO, the PI or study site personnel.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"8 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Concentration Using WC3 as the Viral Lysate","description":"GMC of serum anti-rotavirus IgA antibodies as measured by enzyme linked immunosorbent assay (ELISA) using WC3 (heterologous to vaccine strain) as the viral lysate. WC3 strain of rotavirus used in the ELISA assay was heterologous to the 116E strain contained in the vaccines ROTAVAC 5D® and ROTAVAC®.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":null},{"groupId":"OG001","value":"14.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Immediate Adverse Events","description":"Percentage of participants reporting immediate adverse events after each vaccination","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Solicited Adverse Events","description":"Percentage of participants reporting solicited post-vaccination reactogenicity (fever, diarrhea, vomiting, decreased appetite, irritability, decreased activity level)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null},{"groupId":"OG001","value":"136","spread":null},{"groupId":"OG002","value":"129","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"109","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"109","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Unsolicited Adverse Events","description":"Percentage of participants reporting unsolicited AEs at a rate \\>5%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Serious Adverse Events","description":"Percentage of participants reporting SAEs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Rate in Each of the Three Arms as Measured by ELISA Using WC3 as the Viral Lysate","description":"Seroconversion is defined as a post-vaccination serum anti-rotavirus IgA antibody concentration of at least 20 U/mL if a baseline concentration is \\< 20 U/mL or a post-vaccination serum anti-rotavirus IgA antibody concentration of ≥ 2-fold baseline level if a baseline concentration is ≥ 20 U/mL.\n\nWC3 strain of rotavirus used in the ELISA assay was heterologous to the 116E strain contained in the vaccines ROTAVAC® and ROTAVAC 5D®.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Seropositivity Rate in Each of the Three Vaccine Arms as Measured by ELISA Using WC3 as the Viral Lysate","description":"Seropositivity is defined as serum anti-rotavirus IgA antibody concentration ≥ 20 U/mL. WC3 strain of rotavirus used in the ELISA assay was heterologous to the 116E strain contained in the vaccines ROTAVAC® and ROTAVAC 5D®.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroresponse Rate in Each of the Three Vaccine Arms as Measured by ELISA Using WC3 as the Viral Lysate","description":"Seroresponse will be assessed as a four-fold, three-fold and two- fold rise in antibody concentration from baseline. Seroresponse will be assessed as a four-fold, three-fold and two-fold rise in antibody concentration from baseline. WC3 strain of rotavirus used in the ELISA assay was heterologous to the 116E strain contained in the vaccines ROTAVAC® and ROTAVAC 5D®.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) in Each of the Three Vaccine Arms as Measured by ELISA Using WC3 as the Viral Lysate","description":"GMFR in each of the ROTAVAC 5D®, ROTAVAC® and Rotarix® vaccine arms. WC3 strain of rotavirus used in the ELISA assay was heterologous to the 116E strain contained in the vaccines ROTAVAC® and ROTAVAC 5D®.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"3.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Geometric Mean Concentrations Using Strain 89-12 as the Viral Lysate","description":"GMCs of serum anti-rotavirus IgA antibodies in each of the three vaccine arms. 89-12 strain of Rotavirus used in the ELISA assay was homologous to Rotarix® and was heterologous to the strain contained in ROTAVAC® and ROTAVAC 5D®.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"19.2","spread":null},{"groupId":"OG002","value":"38.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seroconversion Using Strain 89-12 as the Viral Lysate","description":"Seroconversion rate in three vaccine arms. 89-12 strain of Rotavirus used in the ELISA assay was homologous to Rotarix® and was heterologous to the strain contained in ROTAVAC® and ROTAVAC 5D®.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seropositivity Using Strain 89-12 as the Viral Lysate","description":"Seropositivity rate in three vaccine arms. 89-12 strain of Rotavirus used in the ELISA assay was homologous to Rotarix® and was heterologous to the strain contained in ROTAVAC® and ROTAVAC 5D®.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Geometric Mean Fold Rise (GMFR) Using Strain 89-12 as the Viral Lysate","description":"GMFR in the three vaccine arms. 89-12 strain of Rotavirus used in the ELISA assay was homologous to Rotarix® and was heterologous to the strain contained in ROTAVAC® and ROTAVAC 5D®.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"4.9","spread":null},{"groupId":"OG002","value":"8.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":137},"commonTop":["Upper Respiratory Tract Infection","Respiratory Tract Infection","Diarrhoea","Rhinitis","Conjuntivities"]}}}